DGX vs INM · P/E 22, rev $5.94B vs rev $4.9M
Quest Diagnostics Incorporated (DGX) versus InMed Pharmaceuticals Inc (INM) — a side-by-side from cached financials, not a winner call.
Quest Diagnostics Incorporated (DGX) is a diagnostics & research company listed on US.
InMed Pharmaceuticals Inc (INM) is a drug manufacturers - specialty & generic company listed on US.
Latest reported DGX revenue for 2026-06-30 was $5.94B. Net income was $572.0M. DGX currently screens at market cap $19.94B and trailing P/E 22.4.
Latest reported INM revenue for 2025-06-30 was $4.9M. Net income was -$8.2M. INM currently screens at market cap $5.2M.
DGX currently screens at market cap $19.94B and trailing P/E 22.4. INM currently screens at market cap $5.2M.
Not investment advice. Open the DGX and INM stock pages for the full models.
Not investment advice.